Our OncoPanel® Cell-Based Screening and Profiling Service offers a comprehensive portfolio of genetically characterized human cancer cell lines with cell health and functional readouts, drug combination profiling, and predictive genomic biomarker identification to guide oncology therapeutic development – developed by the experienced science team at Eurofins Discovery.
Use OncoPanel to profile your small molecule, biologic, nucleotide therapeutic, nanobody or other innovative therapeutic modality. Be empowered for decision-making with insights on efficacy, data on the influence of genomic biomarkers on the cellular response to your test agent, and useful tools for patient stratification.
When you test with OncoPanel, you’ll gain data-driven insights on 250,000+ assessed genetic aberrations including mRNA overexpression, amplifications, deletions, coding and non-coding mutations, and gain or loss of function mutations. For example: OncoPanel Univariate Genomic Analysis can expedite your progression to clinical trials by identifying genomic features that may predispose patients to a therapeutic response or indicate potential resistance mechanisms. Your benefits include the ability to:
- Determine antiproliferative or cytotoxic activities by screening a large number of early-stage test agents in a subset of cell lines
- Identify predictive genomic biomarkers of response by profiling late-stage assets in a large number of cell lines
- Reveal new cancer indications for existing drugs, or anticancer indications for drugs from other therapeutic areas for repurposing efforts
- Compare test agent responses to reference agents and therapeutics using similarity clustering
Our robust platform provides drug response data from 300+ 2D human cancer cell lines and 100+ 3D tumor spheroid models, spanning 19 different tissue lineages. Test agents may be evaluated across the entire panel of genomically diverse cell lines, all licensed from renowned repositories, or within focused panels curated for specific target pathways including kinases, GPCRs, growth factor receptors, epigenetic targets and more. All genomic analyses reference the 19,000+ genes and 250,000+ genomic features in the database and is included as standard for panels with 200+ cell lines.
Benefits of OncoPanel Screening & Profiling include
- Flexibility to choose from 3-day, 5-day, or 10-day proliferation and viability assays, customized assay timelines considered
- Multiplex readouts for apoptosis induction and cell cycle arrest available for all three time-course options
- Ability for competitive benchmarking to 60+ standards-of-care and tool compounds
- Complex drug combination studies assessed in a 9×9 matrix format to determine synergy, additivity, and antagonism
- Reproducible, reliable data delivered to clients only following rigorous quality-assured/quality-controlled processes
Our expert teams, from Translational Biology and Biotherapeutics to DiscoveryOne™, can plan a program to accommodate your project needs. We have capabilities to accommodate diversity – from numbers of test agents and cell line combinations – to complexity, with singleplex and multiplex data options. Projects are scheduled as quarterly panel runs, with custom studies evaluated based on scope.
With over 15 years of experience delivering actionable insights for clients, our team has worked with a variety of anticancer agents such as kinase inhibitors, nucleotides, biologics, and combination candidates. Let us deliver for you, too.
